Akeso Received Payment for the Development Collaboration on Tagitanlimab

2025-01-26 IDOPRESS

HONG KONG,Jan. 22,2025 -- On January 22,2025,Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co.,Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab,an innovative humanized monoclonal antibody targeting PD-L1,following its recent marketing approval by China's National Medical Products Administration.

In 2014,Akeso signed a cooperation agreement with Sichuan Kelun for the development of tagitanlimab. Under the terms of the agreement,Akeso will receive royalties from the commercial sales of tagitanlimab in addition to the development payment.

Tagitanlimab marks Akeso's second oncology product to yield commercial royalties,following pucotenlimab,a PD-1 monoclonal antibody developed in collaboration with Lepu Biopharma in 2016.

Dr. Yu Xia,founder,chairwoman,president,and CEO of Akeso,said: "Congratulations to our partners. We are thrilled about continuously successful approval of our innovative products,and truly anticipate their outstanding commercialization performance. This achievement highlights Akeso's strong R&D capabilities and our commitment to innovation. Since its inception,Akeso has established multiple external collaborations,including ivonescimab with Summit Therapeutics,quavonlimab with Merck and pucotenlimab with Lepu Biopharma. These partnerships not only benefit patients but also deliver significant returns for both Akeso and our collaborators. Looking ahead,Akeso will continue to pursue a diversified strategy for new drug development,leveraging global resources to drive the high-quality commercialization of our independently developed innovative therapeutics."

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas

Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas

2AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising

AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising

3Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era

Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era

4"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"

"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"

5Congratulations on Hannah Yihan Liu's works participating in the LUV International Art Exhibition!

Congratulations on Hannah Yihan Liu's works participating in the LUV International Art Exhibition!

6Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market

Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market

©copyright 2009-2020 Singapore Info Map